In Depth 5 Nov 2025 Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring Discover how Novo Nordisk’s pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and obesity. November 5, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Jul 2025 10 biotech companies leading the way in Denmark Explore Denmark’s dynamic biotech scene with 10 innovative companies at the forefront of the biopharmaceutical revolution! July 29, 2025 - 16 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 16 Jun 2025 Did Novo open the Canadian market to GLP-1 generics? Find out if Novo’s GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a small fee? June 16, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 25 Mar 2024 Beyond Wegovy: Could Novo Nordisk’s new experimental weight loss pill be even better? Discover how Novo Nordisk’s new experimental obesity pill, amycretin, could be even more efficient for weight loss than Wegovy. March 25, 2024 - 4 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 27 Feb 2024 Can the Novo Holdings-Catalent deal set a new standard for Pharma M&A? Explore the strategic implications of Novo Nordisk’s $16.5B Catalent acquisition on drug supply and market competition. February 27, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 28 Sep 2023 Obesity drug success sparks biotech buying spree The last few months have seen the obesity drug market soar, after new weight loss and diabetes drugs like Novo Nordisk’s Wegovy and Ozempic took the world by storm with their incredible efficacy at inducing weight loss. These new drugs belong to a class of medications called GLP-1 analogs (or incretin-based therapies), which work by […] September 28, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Aspect and Novo Nordisk working on bioprinted tissue for diabetes and obesity Aspect Biosystems and Novo Nordisk A/S are set to collaborate on developing bioprinted tissue therapeutics to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s background in stem cell differentiation […] April 13, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Mar 2023 Debiopharm adds to oncology pipeline Debiopharm, an independent Swiss-based, biopharmaceutical company, has obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway from Novo Nordisk. FT-3171 was developed by Forma Therapeutics, which was acquired by Novo Nordisk in 2022, and is currently in late preclinical development. FT-3171 (Debio 0432) could […] March 3, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023 Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study Heartseed Inc. and Novo Nordisk A/S say Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated four-week data on the patient, who lives with advanced heart failure and has given approval for […] February 10, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 Is Copenhagen the world capital of life science? Denmark’s leading life science companies, public foundations, municipalities, universities and hospitals will work together to position Copenhagen as the world capital of life science through the newly-launched Copenhagen Life Science partnership. Tackling obesity is the first step in this public-private partnership. In 2022, the Danish government invested 82 million DKK ($11.7 million) to strengthen and […] January 17, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 FDA clears insulin pen medical device BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, has received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: “This approval is a major achievement for BIOCORP and all of […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 23 Nov 2022 Novo Nordisk announces $750M facility expansion Novo Nordisk has announced plans to invest DKK 5.4 bn ($750m) in the expansion of existing facilities in Bagsværd, Denmark. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API) to supply global […] November 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email